New England Capital Financial Advisors’s GSK GSK Stock Holding History

New England Capital Financial Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-421	Closed	-$20.6K	–	426
2025 Q4	$20.6K	Buy	421 +5	+1%	+$233	0.01%	189
2025 Q3	$18K	Buy	416 +4	+1%	+$156	0.01%	200
2025 Q2	$15.8K	Buy	412 +5	+1%	+$191	0.01%	202
2025 Q1	$15.8K	Buy	407 +3	+0.7%	+$110	0.01%	201
2024 Q4	$13.7K	Buy	404 +162	+67%	+$5.83K	0.01%	209
2024 Q3	$9.89K	Buy	242 +2	+0.8%	+$82	0.01%	234
2024 Q2	$9.23K	Buy	240 +3	+1%	+$126	0.01%	228
2024 Q1	$10.2K	Buy	237 +2	+0.9%	+$82	0.01%	225
2023 Q4	$8.72K	Buy	235 +2	+0.9%	+$72	0.01%	237
2023 Q3	$8.45K	Buy	233 +2	+0.9%	+$71	0.01%	236
2023 Q2	$8.23K	Buy	231 +1	+0.4%	+$36	0.01%	240
2023 Q1	$8.17K	Buy	230 +100	+77%	+$3.5K	0.01%	266
2022 Q4	$4.59K	Buy	+130	New	+$4.33K	﹤0.01%	303

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

New England Capital Financial Advisors's GSK Position: Q1 2026 in Review

New England Capital Financial Advisors sold out of GSK (GSK) in Q1 2026, closing a stake of 421 shares — an estimated $20.6K sold.

New England Capital Financial Advisors first reported a position in GSK in Q4 2022 and held it in 13 quarters. The position peaked at $20.6K in Q4 2025. 1,033 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

New England Capital Financial Advisors reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
New England Capital Financial Advisors sold 421 GSK shares in Q1 2026, an estimated $20.6K.
New England Capital Financial Advisors first reported a position in GSK in Q4 2022 and held it in 13 quarters.
New England Capital Financial Advisors's GSK position peaked at $20.6K in Q4 2025.
1,033 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on New England Capital Financial Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.